RALEIGH, N.C., Dec. 8 /PRNewswire/ -- CLOSURE Medical Corporation
(Nasdaq: CLSR), today announced that Ronald A. Ahrens, 60, a member of the
Board of the Company since January of this year, has been elected as its
Chairman of the Board. Mr. Ahrens succeeds Rolf D. Schmidt, who co-founded
the company in 1990 and has served as Chairman since inception. Mr. Schmidt
will continue to serve on the board and as chairman of its executive
committee.
Mr. Ahrens has over thirty years experience in the pharmaceutical and
health care industry, with particular emphasis on the consumer marketplace.
Prior to his retirement, Mr. Ahrens served as President of the Consumer
Healthcare Group Worldwide of Merck & Company. Mr. Ahrens joined Merck in
1990 as Executive Vice President of Consumer Healthcare Group International.
Prior to joining Merck, he served in senior executive positions with
Bristol-Myers Squibb and Richardson Vicks.
"As the Company's possibilities expand, we look to Ron Ahrens' wealth of
experience in the health care industry to help us exploit various
opportunities and our growing technology base," said Rolf Schmidt.
Robert V. Toni, President and CEO said, "I am looking forward to working
closely with Ron Ahrens and our Board of Directors in taking advantage of the
enormous opportunities that lie ahead for Closure Medical."
CLOSURE Medical Corporation, headquartered in Raleigh, North Carolina,
develops, manufactures and commercializes medical tissue cohesive products
based on its proprietary cyanoacrylate technology. CLOSURE's nonabsorbable
tissue cohesive products may be used to replace sutures and staples for
certain topical wound closure applications and oral pain relief associated
with canker sores, while its absorbable tissue cohesive products can
potentially be used as tissue cohesives for internal wound closure and
management. Currently marketed nonabsorbable tissue cohesive products include
DERMABOND topical skin adhesive, which is used to replace sutures and staples
for closure of certain lacerations and incisions, OCTYLDENT(R) cohesive, which
is used as an adjunct in the treatment of adult periodontal disease; and
NEXABAND(R) topical cohesives, a family of products used in veterinary wound
closure and management.
*DERMABOND is a trademark of Ethicon, Inc.; OCTYLDENT and NEXABAND are
all trademarks of CLOSURE Medical Corporation.
To receive CLOSURE's latest news release and other corporate documents via
fax, at no cost, call 1-800-PRO-INFO, use the Company's symbol CL
the Financial Relations Board's website at http://www.frbinc.com .
This release contains certain forward-looking statements which involve
known and unknown risks, delays, uncertainties or other factors not under the
Company's control which may cause actual results, performance or achievements
of the Company to be materially different from the results, performance, or
other expectations implied by these forward-looking statements. These factors
include, but are not limited to the early stage of commercialization of the
Company's products; the progress of its research and development programs for
future nonabsorbable and absorbable products; the need for regulatory approval
and effects of governmental regulation; technological uncertainties;
dependence on marketing partners, and dependence on patents and trade secrets,
as well as those detailed in the Company's Annual Report on Form 10-K for the
year ended December 31, 1998 filed with the Securities and Exchange
Commission.
SOURCE CLOSURE Medical Corporation
 back to top
Related links:
http://www.frbinc.com
CONTACT:
Robert V. Toni, President & CEO, J. Blount
Swain, CFO, or Ronald A. Ahrens, Chairman, of CLOSURE Medical
Corporation, 919-876-7800, or General, Paul G. Henning, Analysts,
Brian Gill, or Media, Deanne Eagle, of The Financial Relations
Board, 212-661-8030
|
